PEG-RELIGRAST 6 MG INJ. PFS.

About

PEG-RELIGRAST 6 MG INJ. PFS. is a pegylated form of human granulocyte colony-stimulating factor (G-CSF). It functions by stimulating the production, maturation, and activation of neutrophils, which are a type of white blood cell crucial for fighting infections. This medication is primarily used to reduce the incidence of febrile neutropenia, a serious complication characterized by fever and a dangerously low neutrophil count, in patients receiving myelosuppressive anti-cancer chemotherapy. By boosting neutrophil levels, PEG-RELIGRAST helps to maintain the patient's immune defense, allowing for on-schedule chemotherapy administration and reducing the risk of life-threatening infections. Its long-acting formulation allows for a single dose per chemotherapy cycle.

Uses

• Prevention of febrile neutropenia in chemotherapy
• Treatment of severe chronic neutropenia
• Mobilization of peripheral blood progenitor cells
• Supportive care in certain bone marrow disorders

Directions For Use

Administered as a single subcutaneous injection once per chemotherapy cycle, at least 24 hours after chemotherapy. Do not administer within 14 days before or 24 hours after cytotoxic chemotherapy.

Benefits

• Reduces incidence of febrile neutropenia
• Allows for on-schedule chemotherapy administration
• Improves patient quality of life by reducing infection risk
• Single dose per chemotherapy cycle for convenience
• Well-established safety profile
• Supports immune function during chemotherapy

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Headache
• Fatigue
• Nausea
• Injection site reactions
• Splenic rupture (rare)
• Acute respiratory distress syndrome (rare)
• Allergic reactions
• Glomerulonephritis
• Leukocytosis
• Thrombocytopenia

Safety Measures

• Alcohol - No specific interaction, but excessive alcohol may worsen general health or fatigue.
• Pregnancy - Use only if clearly needed; animal studies show adverse effects. Consult physician.
• Breastfeeding - Unknown if excreted in human milk; use with caution and consult a healthcare provider.
• Liver - No specific dose adjustment required; primarily cleared by neutrophil-mediated degradation.
• Kidney - No specific dose adjustment required; primarily cleared by neutrophil-mediated degradation.
• Lung - Monitor for acute respiratory distress syndrome (ARDS) and interstitial lung disease; discontinue if pulmonary infiltrates develop.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.